Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Looking For A Buyer, Savient Talks Krystexxa Price & Gears Up For Launch

Executive Summary

On the prowl for a buyer after the approval of Krystexxa for refractory gout, Savient Pharmaceuticals assured investors that they have enough product supply to launch by year-end and that it will set a premium price, though it was vague on when it will commit to an exact figure.
Advertisement

Related Content

Savient Seeks Europe Partner For Gout Drug Krystexxa After CHMP Boost
Business & Finance News, In Brief
Business & Finance News, In Brief
Krystexxa Cleared For Refractory Gout, Could Reach Patients By Year's End
As Gout Market Opens Up, Experts Await Therapies To Better Lower Uric Acid
Savient On Track To Resubmit Krystexxa BLA In Early 2010, Exec Maintains

Topics

Advertisement
UsernamePublicRestriction

Register

PS052630

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel